Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
65.67
-1.85 (-2.74%)
At close: Aug 28, 2026, 4:00 PM EDT
65.21
-0.46 (-0.70%)
Pre-market: Aug 31, 2026, 5:11 AM EDT
Travere Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Travere Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $74.14. The average 1-year stock price forecast is 12.90% higher than the current stock price, while the lowest is $62 (-5.59%) and the highest is $90 (+37.05%).
Price Target: $74.14 (+12.90%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Travere Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 12 | 12 | 12 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $49 → $68 | Buy | Maintains | $49 → $68 | +3.55% | Aug 17, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $70 | Buy | Maintains | $70 | +6.59% | Aug 12, 2026 |
| Evercore ISI | Evercore ISI | Buy Reiterates $68 → $78 | Buy | Reiterates | $68 → $78 | +18.78% | Aug 10, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Hold Maintains $43 → $62 | Hold | Maintains | $43 → $62 | -5.59% | Aug 9, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $53 → $90 | Buy | Maintains | $53 → $90 | +37.05% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
724.07M
from 490.73M
Increased by 47.55%
Revenue Next Year
1.08B
from 724.07M
Increased by 49.49%
EPS This Year
1.74
from 0.91
Increased by 90.69%
EPS Next Year
5.67
from 1.74
Increased by 226.88%
EPS and Forward PE are based on non-GAAP adjusted numbers.